Safety of nivolumab in combination with prior or concurrent radiation therapy in hepatocellular carcinoma
ConclusionCombination RT and nivolumab is generally safe in the management of unresectable HCC with a low rate of serious adverse events. Prospective trials investigating the efficacy of combination nivolumab and RT are warranted.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Radiation Therapy | Toxicology | Urology & Nephrology